Curriculum Vitaes
Profile Information
- Affiliation
- Fujita Health University
- Degree
- 博士(医学)(名古屋大学)
- J-GLOBAL ID
- 200901016530045724
- researchmap Member ID
- 1000369036
Research Interests
9Research Areas
1Research History
6-
Apr, 2019 - Present
-
Dec, 2013 - Mar, 2019
-
Jun, 2013 - Nov, 2013
-
Jan, 2009 - May, 2013
-
Apr, 2007 - Dec, 2008
Papers
909-
Alzheimer's Research & Therapy, Apr 20, 2026
-
Brain and nerve = Shinkei kenkyu no shinpo, 78(4) 303-311, Apr, 2026The olfactory nerve possesses unique anatomical features, including direct central nervous system (CNS) projection and continuous regeneration. Scientific advances have elucidated mechanisms such as combinatorial receptor coding and signal amplification. This review summarizes these foundations and examines olfactory dysfunction in COVID-19 and Parkinson's disease (PD). In COVID-19, evidence suggests that SARS-CoV-2 targets sustentacular cells rather than olfactory neurons, causing gene downregulation and parosmia attributed to incomplete peripheral filtering, while direct CNS invasion remains rare. In PD, olfactory loss is a prodromal feature. However, seed amplification assays reveal that alpha-synuclein aggregation in the nasal mucosa does not fully correlate with olfactory dysfunction, as reflected by differences between PD and Multiple System Atrophy. This, together with correlations with cardiac sympathetic denervation, challenges simple pathogen propagation hypotheses. We propose that PD-related hyposmia reflects a systemic vulnerability involving deficits in energy metabolism and neural network organization, rather than solely peripheral protein aggregation. Understanding these pathologies requires a multifaceted approach beyond anatomical lesions.
Misc.
115-
MOVEMENT DISORDERS, 31 S6-S6, Jun, 2016
-
MOVEMENT DISORDERS, 31 S394-S394, Jun, 2016
-
MOVEMENT DISORDERS, 31 S373-S373, Jun, 2016
-
Frontiers in Parkinson disease, 9(2) 72-75, May, 2016
-
MOVEMENT DISORDERS, 31 S23-S23, Mar, 2016
-
144(8) 1616-1618, Nov, 2015
-
神経変性疾患領域における基盤的調査研究 平成26年度 総括・分担研究報告書, 2015
-
CEREBROVASCULAR DISEASES, 39 118-118, 2015
-
BRAIN PATHOLOGY, 24 70-70, Sep, 2014
-
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 19(3) 276-276, Sep, 2014
-
MOVEMENT DISORDERS, 29 S140-S140, May, 2014
-
MOVEMENT DISORDERS, 29 S381-S381, May, 2014
-
MOVEMENT DISORDERS, 28 S73-S73, Jun, 2013
-
NEUROLOGY, 80, Feb, 2013
-
MOVEMENT DISORDERS, 27 S206-S206, Jun, 2012
-
MOVEMENT DISORDERS, 27 S444-S444, Jun, 2012
-
Frontiers in Parkinson disease, 5(2) 88-91, May, 2012
-
STROKE, 42(3) E324-E324, Mar, 2011
-
NEUROLOGY, 72(11) A275-A275, Mar, 2009
-
BMJ case reports, 2009, 2009A 57-year-old man with type 2 diabetes mellitus for 10 years showed progressive loss of muscle strength in both legs, pain and muscle atrophy in the femoral region and significant weight loss. On admission, he could not stand alone and used a wheelchair. He also complained of severe pain in the lower extremities. He was diagnosed with proximal diabetic neuropathy (PDN) by characteristic clinical and electrophysiological features. Intravenous immunoglobulin therapy (IVIg 0.4 g/kg×5 days) markedly reduced the severe pain and muscle weakness in the legs. Eventually, pain assessed by the Visual Analogue Scale was relieved by 80% and muscle strength was also well recovered, thereby enabling the patient to walk with a cane. The present case suggests that IVIg therapy may be effective for the relief of pain in PDN.
-
MOVEMENT DISORDERS, 23(1) S307-S307, 2008
-
16(2) 173-175, Dec 1, 2005
Books and Other Publications
6Professional Memberships
13Research Projects
27-
科学研究費助成事業, 日本学術振興会, Apr, 2025 - Mar, 2029
-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2024 - Mar, 2029
-
科学研究費助成事業, 日本学術振興会, Apr, 2025 - Mar, 2028
-
科学研究費助成事業, 日本学術振興会, Apr, 2022 - Mar, 2026
-
科学研究費助成事業, 日本学術振興会, Apr, 2022 - Mar, 2025